David Frank

Department of Hematology and Medical Oncology
Professor

(404) 778-6510
david.alan.frank@emory.edu

Overview

David A. Frank, MD, PhD, FACP, serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center. Board certified in medical oncology, he cares for patients with hematologic malignancies, specializing in leukemia. He is actively involved in training the next generation of clinical oncologists and cancer scientists.

Dr. Frank is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. He is a Fellow of American College of Physicians. He holds professional memberships with American Association for the Advancement of Science, American Association of Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Microbiology. He serves as chair for the Medical Sciences Section of the American Association for the Advancement of Science.

Prior to joining Emory, Dr. Frank was the chief quality officer for Dana-Farber/Harvard Cancer Center, having previously served as chair of Quality Improvement for Medical Oncology, chair of the Pharmacy and Therapeutics Committee, and medical director of patient safety.

A renowned physician-scientist, Dr. Frank's translational research laboratory focuses on the intracellular signaling pathways that control normal cellular function and become subverted in the development of cancer, and then using this knowledge in designing targeted molecular inhibitors for the treatment of cancer. His lab has developed innovative ways to target STAT transcription factors, leading to a series of therapeutic clinical trials, including the first clinical trial of a small molecule STAT3 inhibitor in cancer therapy.

Dr. Frank has authored or coauthored more than 100 peer-reviewed publications. He serves on the editorial board of Cancer Research, Clinical Cancer Research, and Cancer Biology and Therapy. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, Nature Medicine, Science Signaling, Proceedings of the National Academy of Sciences, and others.

Academic Appointment

Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

MD from Yale University
PhD from Yale University

Research

Publications

Challenging the "Undruggable"Targeting STAT3 but Identifying Potent TrkA-Targeted Inhibitors.
J Med Chem
04/17/2025 Authors: Iliev P; McCutcheon C; Admas TH; Reithmeier A; Lopez McDonald M; van Outryve A; Hanke D; Brown JI; Haraldsson M; Toillon R-A
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes.
Neoplasia Volume: 61 Page(s): 101137
03/01/2025 Authors: King Z; Desai SR; Frank DA; Shastri A
Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.
Front Immunol Volume: 16 Page(s): 1486784
01/01/2025 Authors: Ozuna H; Bojja D; Partida-Sanchez S; Hall-Stoodley L; Amer A; Britt RD; Sheikh S; Frank DA; Wang W; Kang B-Y
Dissecting Out a Rare Mutation, STAT: Features of STAT3-Mutant Myeloid Neoplasms.
Clin Cancer Res Volume: 30 Page(s): 4554 - 4556
10/15/2024 Authors: Hochman MJ; Frank DA
Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants.
PLoS Med Volume: 21 Page(s): e1004470
09/01/2024 Authors: Greulich H; Chen T-H; Feng W; Jnne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR
Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.
Cancers (Basel) Volume: 16
03/31/2024 Authors: Wang W; Lopez McDonald MC; Hariprasad R; Hamilton T; Frank DA
Investigating the anti-cancer potential of pyrimethamine analogues through a modern chemical biology lens.
Eur J Med Chem Volume: 264 Page(s): 115971
01/15/2024 Authors: Brown JI; Persaud R; Iliev P; Karmacharya U; Attarha S; Sahile H; Olsen JE; Hanke D; Idowu T; Frank DA
Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML
Volume: 23 Page(s): S355 - S355
09/01/2023 Authors: Rivera-Pena B; Chakraborty S; Shi Y; Zhang H; Zhao R; Choudhary G; Gordon-Mitchell S; Pradhan K; Fu B; Tosic I
Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers.
Breast Cancer Res Volume: 25 Page(s): 24
03/07/2023 Authors: Hathaway CA; Rice MS; Collins LC; Chen D; Frank DA; Walker S; Clevenger CV; Tamimi RM; Tworoger SS; Hankinson SE
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.
Clin Cancer Res Volume: 29 Page(s): 878 - 887
03/01/2023 Authors: Chen EC; Gandler H; Toi I; Fell GG; Fiore A; Pozdnyakova O; DeAngelo DJ; Galinsky I; Luskin MR; Wadleigh M
Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity.
Metabolites Volume: 13
01/19/2023 Authors: Brown JI; Wang P; Wong AYL; Petrova B; Persaud R; Soukhtehzari S; Lopez McDonald M; Hanke D; Christensen J; Iliev P
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Cancer Res Volume: 83 Page(s): 264 - 284
01/18/2023 Authors: Stevens LE; Peluffo G; Qiu X; Temko D; Fassl A; Li Z; Trinh A; Seehawer M; Jovanovi B; Alekovi M
The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies.
Front Immunol Volume: 14 Page(s): 1265818
01/01/2023 Authors: Wang W; Lopez McDonald MC; Kim C; Ma M; Pan ZT; Kaufmann C; Frank DA
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Mol Oncol Volume: 16 Page(s): 3994 - 4010
12/01/2022 Authors: Yoshikawa Y; Stopsack KH; Wang XV; Chen Y-H; Mazzu YZ; Burton F; Chakraborty G; Rajanala SH; Hirani R; Nandakumar S
Cyclin-Dependent Kinase 4/6 Inhibitors: Is a Noncanonical Substrate the Key Target?
Cancer Res Volume: 82 Page(s): 1170 - 1171
04/01/2022 Authors: Frank DA
Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration.
Cell Rep Volume: 38 Page(s): 110473
03/08/2022 Authors: Ajay AK; Zhao L; Vig S; Fujiwara M; Thakurela S; Jadhav S; Cho A; Chiu I-J; Ding Y; Ramachandran K
The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase.
J Biol Chem Volume: 298 Page(s): 101531
02/01/2022 Authors: Heppler LN; Attarha S; Persaud R; Brown JI; Wang P; Petrova B; Toi I; Burton FB; Flamand Y; Walker SR
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications.
Neoplasia Volume: 23 Page(s): 1167 - 1178
12/01/2021 Authors: Toi I; Frank DA
Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability.
Dis Model Mech Volume: 14
11/01/2021 Authors: Wang L; Astone M; Alam SK; Zhu Z; Pei W; Frank DA; Burgess SM; Hoeppner LH
IL-6 enhances CD4 cell motility by sustaining mitochondrial Ca2+ through the noncanonical STAT3 pathway.
Proc Natl Acad Sci U S A Volume: 118
09/14/2021 Authors: Valena-Pereira F; Fang Q; Mari IJ; Giddings EL; Fortner KA; Yang R; Villarino AV; Huang YH; Frank DA; Wen H
Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
Mol Cancer Res Volume: 19 Page(s): 1283 - 1295
08/01/2021 Authors: Liu S; Gandler HI; Toi I; Ye DQ; Giaccone ZT; Frank DA
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Br J Cancer Volume: 125 Page(s): 582 - 592
08/01/2021 Authors: Lapidot M; Case AE; Weisberg EL; Meng C; Walker SR; Garg S; Ni W; Podar K; Hung YP; Carrasco RD
A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML.
Blood Volume: 137 Page(s): 3403 - 3415
06/17/2021 Authors: Chen B-R; Deshpande A; Barbosa K; Kleppe M; Lei X; Yeddula N; Vela PS; Campos AR; Wechsler-Reya RJ; Bagchi A
Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles.
Mol Cancer Ther Volume: 20 Page(s): 726 - 738
04/01/2021 Authors: Toi I; Heppler LN; Egusquiaguirre SP; Boehnke N; Correa S; Costa DF; Moore EAG; Pal S; Richardson DS; Ivanov AR
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Am J Hematol Volume: 96 Page(s): E95 - E98
04/01/2021 Authors: Brown JR; Walker SR; Heppler LN; Tyekucheva S; Nelson EA; Klitgaard J; Nicolais M; Kroll Y; Xiang M; Yeh JE
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM).
Cancers (Basel) Volume: 13
12/22/2020 Authors: Lapidot M; Case AE; Larios D; Gandler HI; Meng C; Toi I; Weisberg EL; Poitras MJ; Gokhale PC; Paweletz CP
Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability.
bioRxiv
11/20/2020 Authors: Wang L; Astone M; Alam SK; Zhu Z; Pei W; Frank DA; Burgess SM; Hoeppner LH
Targeting STAT3-driven breast cancer cells using layer-by-layer nanoparticles
Volume: 80
08/01/2020 Authors: Tosic I; Heppler LN; Egusquiaguirre SP; Boehnke N; Correa S; Costa D; Haas-Kogan DA; Hammond PT; Frank DA
STAT3 promotes ovarian cancer spheroid growth and metastasis.
Volume: 26 Page(s): 87 - 88
07/01/2020 Authors: Walker DF; Lacroix SJ; Giaccone ZT; Frank DA; Walker SR
Atovaquone targets STAT3 in ovarian cancer spheroids.
Volume: 26 Page(s): 86 - 87
07/01/2020 Authors: Neil KE; Lacroix SJ; Walker DF; Liu S; Frank DA; Walker SR
Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
Bioorg Med Chem Volume: 28 Page(s): 115542
06/15/2020 Authors: Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3.
Neoplasia Volume: 22 Page(s): 47 - 59
01/01/2020 Authors: Egusquiaguirre SP; Liu S; Toi I; Jiang K; Walker SR; Nicolais M; Saw TY; Xiang M; Bartel K; Nelson EA
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Blood Adv Volume: 3 Page(s): 4215 - 4227
12/23/2019 Authors: Stevens AM; Xiang M; Heppler LN; Toi I; Jiang K; Munoz JO; Gaikwad AS; Horton TM; Long X; Narayanan P
Mutant KRAS downregulates LIFR to enhance glycolysis in pancreatic cancer
Volume: 79
12/01/2019 Authors: Liu S; Gandler HI; Walker SR; Ye DQ; Giaccone ZT; Nowak JA; Aguirre AJ; Wolpin BM; Frank DA
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
Volume: 134
11/13/2019 Authors: Garcia JS; Gandler HI; Fell G; Fiore AJ; Neuberg DS; Anderson A; O'Day K; Luskin M; Wadleigh M; Winer ES
Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?
Cancer Cell Volume: 36 Page(s): 459 - 461
11/11/2019 Authors: Heppler LN; Frank DA
A proactive approach to assess system safety in clinical operations at a comprehensive cancer center.
Volume: 37
09/20/2019 Authors: Durney J; Wong L; Breaud AF; Cedro L; Rowell S; Harvey C; Szabatura AH; Kadish S; Frank D; Lane S
Pyrimethamine inhibits STAT3 transcriptional activity via dihydrofolate
Volume: 79
07/01/2019 Authors: Heppler LN; Walker SR; Attarha S; Page BD; Frank DA
Cancer Biomarkers for Integrative Oncology.
Curr Oncol Rep Volume: 21 Page(s): 32
03/05/2019 Authors: Ganguly A; Frank D; Kumar N; Cheng Y-C; Chu E
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts.
Oncogenesis Volume: 8 Page(s): 15
02/22/2019 Authors: Chen C-H; Bhasin S; Khanna P; Joshi M; Joslin PM; Saxena R; Amin S; Liu S; Sindhu S; Walker SR
The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
Blood Adv Volume: 2 Page(s): 3428 - 3442
12/11/2018 Authors: Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
J Clin Invest Volume: 128 Page(s): 5479 - 5488
12/03/2018 Authors: Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O
IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.
Cancer Res Volume: 78 Page(s): 4957 - 4970
09/01/2018 Authors: Karakasheva TA; Lin EW; Tang Q; Qiao E; Waldron TJ; Soni M; Klein-Szanto AJ; Sahu V; Basu D; Ohashi S
Gene expression network--based identification of drugs targeting advanced ovarian cancer.
Volume: 24 Page(s): 82 - 82
08/01/2018 Authors: Walker SR; Giaccone ZT; Frank DA
The STAT3 Target Gene TNFRSF1A Modulates the NF-B Pathway in Breast Cancer Cells.
Neoplasia Volume: 20 Page(s): 489 - 498
05/01/2018 Authors: Egusquiaguirre SP; Yeh JE; Walker SR; Liu S; Frank DA
Rare mutations provide unique insight into oncogenic potential of STAT transcription factors.
J Clin Invest Volume: 128 Page(s): 113 - 115
01/02/2018 Authors: Heppler LN; Frank DA
The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer.
Cancer Immunol Immunother Volume: 67 Page(s): 13 - 23
01/01/2018 Authors: Khan MW; Saadalla A; Ewida AH; Al-Katranji K; Al-Saoudi G; Giaccone ZT; Gounari F; Zhang M; Frank DA; Khazaie K
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.
Trends Cancer Volume: 3 Page(s): 816 - 827
12/01/2017 Authors: Heppler LN; Frank DA
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.
J Natl Cancer Inst Monogr Volume: 2017
11/01/2017 Authors: Xi D; Bao T; Chen Q; Chen S; Cheng Y-C; Cullen J; Frank DA; Friedberg JW; Kronish I; Lee JE
Evaluation of Patient and Family Outpatient Complaints as a Strategy to Prioritize Efforts to Improve Cancer Care Delivery.
Jt Comm J Qual Patient Saf Volume: 43 Page(s): 498 - 507
10/01/2017 Authors: Mack JW; Jacobson J; Frank D; Cronin AM; Horvath K; Allen V; Wind J; Schrag D
FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)
Volume: 128
12/02/2016 Authors: Adamia S; Nemeth J; Bhatt S; Walker SR; Voeks NI; Lento W; Attar RM; Galinsky I; Frank DA; Wadleigh M
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Blood Volume: 128 Page(s): 1845 - 1853
10/06/2016 Authors: Xiang M; Kim H; Ho VT; Walker SR; Bar-Natan M; Anahtar M; Liu S; Toniolo PA; Kroll Y; Jones N
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.
Oncotarget Volume: 7 Page(s): 51651 - 51664
08/09/2016 Authors: Laidlaw KME; Berhan S; Liu S; Silvestri G; Holyoake TL; Frank DA; Aggarwal B; Bonner MY; Perrotti D; Jrgensen HG
Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.
Oncotarget Volume: 7 Page(s): 46301 - 46314
07/19/2016 Authors: Toniolo PA; Liu S; Yeh JE; Ye DQ; Barbuto JAM; Frank DA
STAT3-Interacting Proteins as Modulators of Transcription Factor Function: Implications to Targeted Cancer Therapy.
ChemMedChem Volume: 11 Page(s): 795 - 801
04/19/2016 Authors: Yeh JE; Frank DA
Targeting transcriptional networks for ovarian cancer therapy.
Volume: 22
01/15/2016 Authors: Walker SR; Zhang Y; Bartel K; Kroll Y; Frank DA
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.
Cell Discov Volume: 2 Page(s): 16030
01/01/2016 Authors: Yuzugullu H; Von T; Thorpe LM; Walker SR; Roberts TM; Frank DA; Zhao JJ
Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3.
Cancer Cytopathol Volume: 123 Page(s): 696 - 706
12/01/2015 Authors: Lowe AC; Pignon J-C; Carvo I; Drage MG; Constantine NM; Jones N; Kroll Y; Frank DA; Signoretti S; Cibas ES
Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.
Mol Cell Biol Volume: 35 Page(s): 3284 - 3300
10/01/2015 Authors: Hu T; Yeh JE; Pinello L; Jacob J; Chakravarthy S; Yuan G-C; Chopra R; Frank DA
Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways.
J Biol Chem Volume: 290 Page(s): 23553 - 23562
09/25/2015 Authors: Byun S; Lim S; Mun JY; Kim KH; Ramadhar TR; Farrand L; Shin SH; Thimmegowda NR; Lee HJ; Frank DA
Development of Selective Covalent Janus Kinase 3 Inhibitors.
J Med Chem Volume: 58 Page(s): 6589 - 6606
08/27/2015 Authors: Tan L; Akahane K; McNally R; Reyskens KMSE; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K
SOCS5 mediates defective function of monocyte-derived dendritic cells in patients with chronic lymphocytic leukemia
Volume: 75
08/01/2015 Authors: Toniolo PA; Liu S; Walker SR; Barbuto JAM; Frank DA
Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics.
J Proteome Res Volume: 14 Page(s): 2367 - 2384
06/05/2015 Authors: Kreimer S; Belov AM; Ghiran I; Murthy SK; Frank DA; Ivanov AR
Granulin, a novel STAT3-interacting protein, promotes breast cancer tumorigenicity
Volume: 75
05/01/2015 Authors: Yeh JE; Kreimer S; Walker SR; Richardson A; Ivanov AR; Frank DA
Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.
J Immunol Volume: 194 Page(s): 3180 - 3190
04/01/2015 Authors: Toniolo PA; Liu S; Yeh JE; Moraes-Vieira PM; Walker SR; Vafaizadeh V; Barbuto JAM; Frank DA
Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer.
Genes Cancer Volume: 6 Page(s): 153 - 168
03/01/2015 Authors: Yeh JE; Kreimer S; Walker SR; Emori MM; Krystal H; Richardson A; Ivanov AR; Frank DA
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.
Oncogene Volume: 34 Page(s): 1073 - 1082
02/26/2015 Authors: Walker SR; Liu S; Xiang M; Nicolais M; Hatzi K; Giannopoulou E; Elemento O; Cerchietti L; Melnick A; Frank DA
Targeting BCL6 and STAT3 in triple negative breast cancer: the one-two punch?
Oncoscience Volume: 2 Page(s): 912
01/01/2015 Authors: Walker SR; Frank DA
Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine
Volume: 124
12/06/2014 Authors: Shastri A; Schinke C; Yanovsky AV; Bhagat TD; Giricz O; Barreyro L; Boultwood J; Pellagati A; Yu Y; Brown JR
Strategies for Targeting Cancer Pathways: Oncogenic Transcription Factors as Convergence Points for Molecular Therapy
Volume: 67 Page(s): 53 - 53
11/01/2014 Authors: Frank D
ACP Journal Club. Review: Self-collected samples are less accurate for HPV testing than clinician-collected samples.
Ann Intern Med Volume: 161 Page(s): JC11
08/19/2014 Authors: Frank DA; Marrazzo J
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Mol Cancer Ther Volume: 13 Page(s): 1194 - 1205
05/01/2014 Authors: Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE
STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b.
Cancers (Basel) Volume: 6 Page(s): 958 - 968
04/23/2014 Authors: Walker SR; Xiang M; Frank DA
Fold change of nuclear NF-B determines TNF-induced transcription in single cells.
Mol Cell Volume: 53 Page(s): 867 - 879
03/20/2014 Authors: Lee REC; Walker SR; Savery K; Frank DA; Gaudet S
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-B to IL-6 signaling axis and STAT3-driven cancer phenotypes.
Sci Signal Volume: 7 Page(s): ra11
01/28/2014 Authors: Xiang M; Birkbak NJ; Vafaizadeh V; Walker SR; Yeh JE; Liu S; Kroll Y; Boldin M; Taganov K; Groner B
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.
Mol Cell Endocrinol Volume: 382 Page(s): 616 - 621
01/25/2014 Authors: Walker SR; Xiang M; Frank DA
A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury.
J Am Soc Nephrol Volume: 25 Page(s): 105 - 118
01/01/2014 Authors: Ajay AK; Kim T-M; Ramirez-Gonzalez V; Park PJ; Frank DA; Vaidya VS
Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer.
J Clin Oncol Volume: 31 Page(s): 4560 - 4561
12/20/2013 Authors: Frank DA
ACP Journal Club. Review: low-dose CT screening reduces lung cancer and mortality in current or former smokers.
Ann Intern Med Volume: 159 Page(s): JC3
11/19/2013 Authors: Lathan C; Frank DA
Targeting transcription factors: promising new strategies for cancer therapy.
Curr Opin Oncol Volume: 25 Page(s): 652 - 658
11/01/2013 Authors: Yeh JE; Toniolo PA; Frank DA
Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Br J Haematol Volume: 163 Page(s): 182 - 193
10/01/2013 Authors: Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.
JAKSTAT Volume: 2 Page(s): e24635
10/01/2013 Authors: Yeh JE; Toniolo PA; Frank DA
STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.
Mol Cell Biol Volume: 33 Page(s): 2879 - 2890
08/01/2013 Authors: Walker SR; Nelson EA; Yeh JE; Pinello L; Yuan G-C; Frank DA
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.
Nat Genet Volume: 45 Page(s): 131 - 132
02/01/2013 Authors: Chmielecki J; Crago AM; Rosenberg M; O'Connor R; Walker SR; Ambrogio L; Auclair D; McKenna A; Heinrich MC; Frank DA
Targeting STATs for cancer therapy: "Undruggable" no more.
JAKSTAT Volume: 1 Page(s): 261 - 262
10/01/2012 Authors: Frank DA
Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets.
JAKSTAT Volume: 1 Page(s): 292 - 299
10/01/2012 Authors: Walker SR; Frank DA
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Proc Natl Acad Sci U S A Volume: 109 Page(s): 14476 - 14481
09/04/2012 Authors: Greulich H; Kaplan B; Mertins P; Chen T-H; Tanaka KE; Yun C-H; Zhang X; Lee S-H; Cho J; Ambrogio L
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
Genes Cancer Volume: 3 Page(s): 503 - 511
07/01/2012 Authors: Nelson EA; Walker SR; Xiang M; Weisberg E; Bar-Natan M; Barrett R; Liu S; Kharbanda S; Christie AL; Nicolais M
Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.
Leukemia Volume: 26 Page(s): 1407 - 1410
06/01/2012 Authors: Bar-Natan M; Nelson EA; Walker SR; Kuang Y; Distel RJ; Frank DA
Evidence for a napdh oxidase-stat5 pathway in human melanoma
Volume: 132 Page(s): S26 - S26
05/01/2012 Authors: Arbiser JL; Bonner MY; Cerulli R; Liu S; Frank DA
Identification of BCL6 targeted therapies for breast cancer through gene expression networks
Volume: 72
04/15/2012 Authors: Walker SR; Cerchietti LC; Nicolais MC; Yuan G-C; Melnick A; Frank DA
Oncogenic extracellular domain mutations of ERBB2 in cancer
Volume: 72
04/15/2012 Authors: Greulich H; Kaplan B; Mertins P; Chen T-H; Tanaka K; Yun C-H; Imielinski M; Banerji S; Lawrence MS; Walker S
STAT signaling in the pathogenesis and treatment of myeloid malignancies.
JAKSTAT Volume: 1 Page(s): 55 - 64
04/01/2012 Authors: Bar-Natan M; Nelson EA; Xiang M; Frank DA
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
Hum Mol Genet Volume: 20 Page(s): 4143 - 4154
11/01/2011 Authors: Takakura A; Nelson EA; Haque N; Humphreys BD; Zandi-Nejad K; Frank DA; Zhou J
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Cancer Biol Ther Volume: 12 Page(s): 9 - 46
07/01/2011 Authors: Catenacci DVT; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brgelmann J; Seiwert T
The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors.
J Clin Invest Volume: 121 Page(s): 2723 - 2735
07/01/2011 Authors: Marotta LLC; Almendro V; Marusyk A; Shipitsin M; Schemme J; Walker SR; Bloushtain-Qimron N; Kim JJ; Choudhury SA; Maruyama R
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation.
Oncotarget Volume: 2 Page(s): 518 - 524
06/01/2011 Authors: Nelson EA; Sharma SV; Settleman J; Frank DA
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
Blood Volume: 117 Page(s): 3421 - 3429
03/24/2011 Authors: Nelson EA; Walker SR; Weisberg E; Bar-Natan M; Barrett R; Gashin LB; Terrell S; Klitgaard JL; Santo L; Addorio MR
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.
Clin Cancer Res Volume: 17 Page(s): 1452 - 1462
03/15/2011 Authors: Morikawa T; Baba Y; Yamauchi M; Kuchiba A; Nosho K; Shima K; Tanaka N; Huttenhower C; Frank DA; Fuchs CS
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
PLoS One Volume: 6 Page(s): e25351
01/01/2011 Authors: Weisberg E; Ray A; Nelson E; Adamia S; Barrett R; Sattler M; Zhang C; Daley JF; Frank D; Fox E
STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.
Mol Cell Pharmacol Volume: 3 Page(s): 13 - 19
01/01/2011 Authors: Walker SR; Chaudhury M; Frank DA
Preclinical Evaluation of a STAT3 Inhibitor in Breast Cancer
Volume: 70
12/15/2010 Authors: Walker SR; Nelson EA; Chaudhury M; Madoux F; Subramaniam P; Chase P; Koenig M; Roush WR; Hodder P; Frank DA
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Leukemia Volume: 24 Page(s): 2100 - 2109
12/01/2010 Authors: Weisberg E; Ray A; Barrett R; Nelson E; Christie AL; Porter D; Straub C; Zawel L; Daley JF; Lazo-Kallanian S
Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.
Mol Pharmacol Volume: 78 Page(s): 903 - 908
11/01/2010 Authors: Walker SR; Chaudhury M; Nelson EA; Frank DA
Targeting STATs for the molecular therapy of lung cancer: Translation from the lab to the clinic
Volume: 5 Page(s): S215 - S215
06/01/2010 Authors: Frank DA
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Proc Natl Acad Sci U S A Volume: 107 Page(s): 252 - 257
01/05/2010 Authors: Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C
Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.
Volume: 114 Page(s): 756 - 756
11/20/2009 Authors: Bar-Natan M; Nelson EA; Walker SR; Barrett R; Frank DA
STAT6 in PMBL: pathogenic or passenger?
Blood Volume: 114 Page(s): 1133 - 1134
08/06/2009 Authors: Frank DA
Reciprocal effects of STAT5 and STAT3 in breast cancer.
Mol Cancer Res Volume: 7 Page(s): 966 - 976
06/01/2009 Authors: Walker SR; Nelson EA; Zou L; Chaudhury M; Signoretti S; Richardson A; Frank DA
CRLF2 is a proto-oncogene in pre-B acute lymphoblastic leukemia with normal cytogenetics
Volume: 69
05/01/2009 Authors: Yoda A; Bar-Natan M; Sattler M; Ritz J; Frank D; Weinstock D
CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.
Clin Cancer Res Volume: 15 Page(s): 2583 - 2587
04/15/2009 Authors: Sakamoto KM; Frank DA
A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brain.
J Neurosci Volume: 29 Page(s): 4312 - 4321
04/01/2009 Authors: Ikeuchi Y; Stegmller J; Netherton S; Huynh MA; Masu M; Frank D; Bonni S; Bonni A
Targeting transcription factors for cancer therapy.
IDrugs Volume: 12 Page(s): 29 - 33
01/01/2009 Authors: Frank DA
Expression of Phospho(p)STAT3 and Phospho(p)STAT5 in Breast Cancer and Correlation with Plasma Prolactin Levels
Volume: 89 Page(s): 30A - 30A
01/01/2009 Authors: Belsley NA; Collins LC; Rice MS; Walker S; Tworoger S; Frank DA
Expression of Phospho(p)STAT3 and Phospho(p)STAT5 in Breast Cancer and Correlation with Plasma Prolactin Levels
Volume: 22 Page(s): 30A - 30A
01/01/2009 Authors: Belsley NA; Collins LC; Rice MS; Walker S; Tworoger S; Frank DA
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
Blood Volume: 112 Page(s): 5095 - 5102
12/15/2008 Authors: Nelson EA; Walker SR; Kepich A; Gashin LB; Hideshima T; Ikeda H; Chauhan D; Anderson KC; Frank DA
Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
J Neurosci Volume: 28 Page(s): 5870 - 5878
06/04/2008 Authors: de la Iglesia N; Konopka G; Lim K-L; Nutt CL; Bromberg JF; Frank DA; Mischel PS; Louis DN; Bonni A
STAT1 expression is not required for polyp formation in Min mice.
Mol Carcinog Volume: 47 Page(s): 75 - 79
02/01/2008 Authors: Liddle FJ; Frank DA
Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer.
ACP J Club Volume: 148 Page(s): 7
01/01/2008 Authors: Frank DA
Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.
Clin Cancer Res Volume: 13 Page(s): 5665 - 5669
10/01/2007 Authors: Germain D; Frank DA
STAT3 as a central mediator of neoplastic cellular transformation.
Cancer Lett Volume: 251 Page(s): 199 - 210
06/28/2007 Authors: Frank DA
A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells.
Cancer Res Volume: 67 Page(s): 1254 - 1261
02/01/2007 Authors: Lynch RA; Etchin J; Battle TE; Frank DA
STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
Oncogene Volume: 26 Page(s): 224 - 233
01/11/2007 Authors: Walker SR; Nelson EA; Frank DA
A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis.
Transl Oncogenomics Volume: 2 Page(s): 99 - 105
01/01/2007 Authors: Alvarez JV; Mukherjee N; Chakravarti A; Robe P; Zhai G; Chakladar A; Loeffler J; Black P; Frank DA
Nifuroxazide inhibits STAT3 function. and shows potent anti-tumor activity against multiple myeloma.
Volume: 108 Page(s): 985A - 985A
11/16/2006 Authors: Nelson EA; Hideshima T; Gashin L; Walker SR; Lynch RA; Chauhan D; Anderson KC; Frank DA
Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with protein kinase C delta and tyrosine-phosphorylated Stat3.
J Immunol Volume: 177 Page(s): 3771 - 3781
09/15/2006 Authors: Bhattacharjee A; Xu B; Frank DA; Feldman GM; Cathcart MK
Identification of human STAT5-dependent gene regulatory elements based on interspecies homology.
J Biol Chem Volume: 281 Page(s): 26216 - 26224
09/08/2006 Authors: Nelson EA; Walker SR; Li W; Liu XS; Frank DA
Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
J Natl Cancer Inst Volume: 98 Page(s): 1238 - 1247
09/06/2006 Authors: Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
Blood Volume: 108 Page(s): 1571 - 1579
09/01/2006 Authors: Zorn E; Nelson EA; Mohseni M; Porcheray F; Kim H; Litsa D; Bellucci R; Raderschall E; Canning C; Soiffer RJ
Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar.
J Invest Dermatol Volume: 126 Page(s): 1396 - 1402
06/01/2006 Authors: Arbiser JL; Govindarajan B; Battle TE; Lynch R; Frank DA; Ushio-Fukai M; Perry BN; Stern DF; Bowden GT; Liu A
Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants.
Biochemistry Volume: 45 Page(s): 5599 - 5605
05/02/2006 Authors: Liddle FJ; Alvarez JV; Poli V; Frank DA
Selective induction of apoptosis by cyclin D1
Volume: 66
04/01/2006 Authors: Ishii Y; Alvarez JV; Frank DA; Waxman S; Germain D
Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis.
Cancer Res Volume: 66 Page(s): 3649 - 3657
04/01/2006 Authors: Battle TE; Lynch RA; Frank DA
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Cancer Res Volume: 66 Page(s): 3162 - 3168
03/15/2006 Authors: Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with PKC delta and tyrosine phosphorylated Stat3
Volume: 20 Page(s): A635 - A635
03/06/2006 Authors: Bhattacharjee A; Xu B; Frank D; Feldman G; Cathcart M
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
Hepatology Volume: 42 Page(s): 1329 - 1338
12/01/2005 Authors: Isomoto H; Kobayashi S; Werneburg NW; Bronk SF; Guicciardi ME; Frank DA; Gores GJ
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
PLoS Med Volume: 2 Page(s): e313
11/01/2005 Authors: Greulich H; Chen T-H; Feng W; Jnne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.
Leuk Res Volume: 29 Page(s): 1009 - 1018
09/01/2005 Authors: Kay NE; Bone ND; Lee YK; Jelinek DF; Leland P; Battle TE; Frank DA; Puri RK
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Blood Volume: 106 Page(s): 690 - 697
07/15/2005 Authors: Battle TE; Arbiser J; Frank DA
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
Cancer Res Volume: 65 Page(s): 5054 - 5062
06/15/2005 Authors: Alvarez JV; Febbo PG; Ramaswamy S; Loda M; Richardson A; Frank DA
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.
Proc Natl Acad Sci U S A Volume: 102 Page(s): 175 - 179
01/04/2005 Authors: Cerimele F; Battle T; Lynch R; Frank DA; Murad E; Cohen C; Macaron N; Sixbey J; Smith K; Watnick RS
Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification.
J Biol Chem Volume: 279 Page(s): 54724 - 54730
12/24/2004 Authors: Nelson EA; Walker SR; Alvarez JV; Frank DA
Molecular events underlying the induced differentiation of CLL cells are recapitulated in CESS B cells.
Volume: 104 Page(s): 277B - 277B
11/16/2004 Authors: Battle TE; Frank DA
The natural product honokiol induces caspase-dependent apoptosis in chronic lymphocytic leukmemia (CLL) cells.
Volume: 104 Page(s): 277B - 277B
11/16/2004 Authors: Battle TE; Arbiser J; Frank DA
IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor.
Carcinogenesis Volume: 25 Page(s): 2247 - 2255
11/01/2004 Authors: Yuan H; Liddle FJ; Mahajan S; Frank DA
Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis.
Cancer Biol Ther Volume: 3 Page(s): 1045 - 1050
11/01/2004 Authors: Alvarez JV; Frank DA
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
Leuk Res Volume: 28 Page(s): 139 - 147
02/01/2004 Authors: Friedberg JW; Dong DA; Li S; Kim H; Stephans K; Noonan K; Neuberg D; Gribben JG; Fisher DC; Freedman AS
Her2 amplifies the opposing roles of STAT3 and STAT5 in breast cancer.
Volume: 88 Page(s): S215 - S215
01/01/2004 Authors: Walker SR; Frank DA
STAT1 activation is associated with induced differentiation of human B cells.
Volume: 102 Page(s): 352B - 352B
11/16/2003 Authors: Battle TE; Frank D
STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.
Blood Volume: 102 Page(s): 3016 - 3024
10/15/2003 Authors: Battle TE; Frank DA
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo.
J Biol Chem Volume: 278 Page(s): 35501 - 35507
09/12/2003 Authors: Bai X; Cerimele F; Ushio-Fukai M; Waqas M; Campbell PM; Govindarajan B; Der CJ; Battle T; Frank DA; Ye K
Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis.
Leuk Res Volume: 27 Page(s): 859 - 863
09/01/2003 Authors: Battle TE; Castro-Malaspina H; Gribben JG; Frank DA
Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3.
Mol Cell Biol Volume: 23 Page(s): 3918 - 3928
06/01/2003 Authors: Xu B; Bhattacharjee A; Roy B; Xu H-M; Anthony D; Frank DA; Feldman GM; Cathcart MK
In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response.
Clin Cancer Res Volume: 9 Page(s): 2166 - 2172
06/01/2003 Authors: Battle TE; Wierda WG; Rassenti LZ; Zahrieh D; Neuberg D; Kipps TJ; Frank DA
IL-13 induction of 15-Lipoxygenase gene expression requires p38 MAPK-dependent serine phosphorylation of Stat1 and Stat3
Volume: 17 Page(s): A1354 - A1354
03/17/2003 Authors: Xu B; Bhattacharjee A; Roy B; Xu HM; Frank DA; Feldman GM; Cathcart MK
PKCdelta regulates IL-13-induced Stat3 serine (727) phosphorylation and 15-lipoxygenase gene expression
Volume: 17 Page(s): A1354 - A1354
03/17/2003 Authors: Bhattacharjee A; Xu B; Roy B; Frank DA; Feldman GM; Cathcart MK
StAT signaling in cancer: insights into pathogenesis and treatment strategies.
Cancer Treat Res Volume: 115 Page(s): 267 - 291
01/01/2003 Authors: Frank DA
Oral fludarabine (FMP) is highly active in patients (pts) with previously untreated chronic lymphocytic leukemia (CLL), and leads to increased STAT1 levels in vivo.
Volume: 100 Page(s): 388A - 388A
11/16/2002 Authors: Friedberg JW; Dong DA; Li SG; Kim H; Stephans K; Noonan K; Neuberg D; Gribben JG; Freedman AS; Takvorian T
The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): molecular basis and clinical relevance.
Leuk Lymphoma Volume: 43 Page(s): 1179 - 1187
06/01/2002 Authors: Duarte RF; Frank DA
The role of STATs in apoptosis.
Curr Mol Med Volume: 2 Page(s): 381 - 392
06/01/2002 Authors: Battle TE; Frank DA
The ribosomal S6 kinases, cAMP-responsive element-binding, and STAT3 proteins are regulated by different leukemia inhibitory factor signaling pathways in mouse embryonic stem cells.
J Biol Chem Volume: 276 Page(s): 46204 - 46211
12/07/2001 Authors: Boeuf H; Merienne K; Jacquot S; Duval D; Zeniou M; Hauss C; Reinhardt B; Huss-Garcia Y; Dierich A; Frank DA
Activation of the STAT signaling pathway is required for CLL differentiation in response to bryostatin 1.
Volume: 98 Page(s): 472A - 472A
11/16/2001 Authors: Battle T; Frank D
CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.
Int J Oncol Volume: 19 Page(s): 791 - 798
10/01/2001 Authors: Vonderheide RH; Butler MO; Liu JF; Battle TE; Hirano N; Gribben JG; Frank DA; Schultze JL; Nadler LM
The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms.
Am J Pathol Volume: 159 Page(s): 483 - 491
08/01/2001 Authors: Arbiser JL; Yeung R; Weiss SW; Arbiser ZK; Amin MB; Cohen C; Frank D; Mahajan S; Herron GS; Yang J
A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation.
Blood Volume: 97 Page(s): 2230 - 2237
04/15/2001 Authors: Barber DL; Beattie BK; Mason JM; Nguyen MH; Yoakim M; Neel BG; D'Andrea AD; Frank DA
CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells.
Exp Hematol Volume: 29 Page(s): 209 - 220
02/01/2001 Authors: Mahajan S; Gollob JA; Ritz J; Frank DA
The treatment and outcome of cancer patients with thromboses on central venous catheters.
J Thromb Thrombolysis Volume: 10 Page(s): 271 - 275
12/01/2000 Authors: Frank DA; Meuse J; Hirsch D; Ibrahim JG; van den Abbeele AD
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Am J Pathol Volume: 157 Page(s): 1937 - 1945
12/01/2000 Authors: LaMontagne KR; Moses MA; Wiederschain D; Mahajan S; Holden J; Ghazizadeh H; Frank DA; Arbiser JL
CD154 (CD40-ligand) gene therapy for chronic lymphocytic leukemia leads to in vivo activation of the STAT1 signaling pathway.
Volume: 96 Page(s): 157A - 157A
11/16/2000 Authors: Battle TE; Wierda WG; Rassenti LZ; Kipps TJ; Frank DA
SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways.
Blood Volume: 96 Page(s): 3422 - 3430
11/15/2000 Authors: Duarte RF; Frank DA
Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections.
J Immunol Volume: 165 Page(s): 4120 - 4126
10/01/2000 Authors: Gollob JA; Veenstra KG; Jyonouchi H; Kelly AM; Ferrieri P; Panka DJ; Altare F; Fieschi C; Casanova JL; Frank DA
STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression.
Cell Immunol Volume: 202 Page(s): 124 - 135
06/15/2000 Authors: Karras JG; McKay RA; Lu T; Pych J; Frank DA; Rothstein TL; Monia BP
STAT signaling in the pathogenesis and treatment of leukemias.
Oncogene Volume: 19 Page(s): 2496 - 2504
05/15/2000 Authors: Lin TS; Mahajan S; Frank DA
Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4.
Blood Volume: 95 Page(s): 3183 - 3190
05/15/2000 Authors: Wang KS; Frank DA; Ritz J
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
Exp Hematol Volume: 28 Page(s): 584 - 593
05/01/2000 Authors: Wilbanks AM; Mahajan S; Frank DA; Druker BJ; Gilliland DG; Carroll M
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.
Blood Volume: 95 Page(s): 2118 - 2125
03/15/2000 Authors: Sillaber C; Gesbert F; Frank DA; Sattler M; Griffin JD
[The JAK-STAT signaling pathway and its role in oncogenesis, immunomodulation and development].
Med Clin (Barc) Volume: 114 Page(s): 227 - 234
02/19/2000 Authors: Duarte RF; Frank DA
SCF and G-CSF lead to the synergistic induction of gene expression through the activation of STATs and complementary signaling pathways.
Volume: 94 Page(s): 263A - 263A
11/15/1999 Authors: Duarte RF; Frank DA
STAT5 activation contributes to growth and viability in BCR/ABL transformed cells.
Volume: 94 Page(s): 632A - 632A
11/15/1999 Authors: Sillaber C; Gesbert F; Frank DA; Sattler M; Griffin JD
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.
Mol Cell Biol Volume: 19 Page(s): 7519 - 7528
11/01/1999 Authors: Turkson J; Bowman T; Adnane J; Zhang Y; Djeu JY; Sekharam M; Frank DA; Holzman LB; Wu J; Sebti S
STAT signaling in the pathogenesis and treatment of cancer.
Mol Med Volume: 5 Page(s): 432 - 456
07/01/1999 Authors: Frank DA
Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Blood Volume: 93 Page(s): 4354 - 4364
06/15/1999 Authors: Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
HTLV-I-infected T cells evade the antiproliferative action of IFN-beta.
Virology Volume: 257 Page(s): 314 - 321
05/10/1999 Authors: Smith D; Buckle GJ; Hafler DA; Frank DA; Hllsberg P
The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation.
J Immunol Volume: 162 Page(s): 4472 - 4481
04/15/1999 Authors: Gollob JA; Schnipper CP; Murphy EA; Ritz J; Frank DA
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
Nat Med Volume: 5 Page(s): 444 - 447
04/01/1999 Authors: Frank DA; Mahajan S; Ritz J
IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells.
J Immunol Volume: 162 Page(s): 299 - 304
01/01/1999 Authors: Wang KS; Ritz J; Frank DA
BCR/ABL kinase activity and the C-terminus of STAT5 are required for BCR/ABL STAT5 interaction.
Volume: 92 Page(s): 90A - 90A
11/15/1998 Authors: Sillaber C; Sattler M; Merchav S; Frank DA; Griffin JD
Fludarabine inhibits STAT1 signaling in normal T cells and CLL cells.
Volume: 92 Page(s): 677A - 677A
11/15/1998 Authors: Frank DA; Mahajan S; Ritz J
Activation of T cells through CD2 leads to the delayed and prolonged activation of STAT1.
Volume: 92 Page(s): 701A - 701A
11/15/1998 Authors: Frank DA; Mahajan S; Ritz J
Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.
J Clin Invest Volume: 102 Page(s): 561 - 575
08/01/1998 Authors: Gollob JA; Schnipper CP; Orsini E; Murphy E; Daley JF; Lazo SB; Frank DA; Neuberg D; Ritz J
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1.
Blood Volume: 91 Page(s): 1341 - 1354
02/15/1998 Authors: Gollob JA; Murphy EA; Mahajan S; Schnipper CP; Ritz J; Frank DA
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.
J Clin Invest Volume: 100 Page(s): 3140 - 3148
12/15/1997 Authors: Frank DA; Mahajan S; Ritz J
The TEL-PDGF beta R transforming protein activates STAT1.
Volume: 90 Page(s): 789 - 789
11/15/1997 Authors: Palmer AM; Mahajan S; Frank D; Gilliland DG; Carroll M
Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement.
J Immunol Volume: 159 Page(s): 4350 - 4355
11/01/1997 Authors: Karras JG; Wang Z; Huo L; Frank DA; Rothstein TL
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway.
Science Volume: 278 Page(s): 477 - 483
10/17/1997 Authors: Bonni A; Sun Y; Nadal-Vicens M; Bhatt A; Frank DA; Rozovsky I; Stahl N; Yancopoulos GD; Greenberg ME
STAT-5 overexpresion enhances proliferation and inhibits the differentiation of murine erythroleukemia cells.
Volume: 25 Page(s): 536 - 536
08/01/1997 Authors: Krispel L; DAndrea AD; Frank D; Merchav S
Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes.
J Exp Med Volume: 185 Page(s): 1035 - 1042
03/17/1997 Authors: Karras JG; Wang Z; Huo L; Howard RG; Frank DA; Rothstein TL
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.
Proc Natl Acad Sci U S A Volume: 94 Page(s): 861 - 866
02/04/1997 Authors: Arbiser JL; Moses MA; Fernandez CA; Ghiso N; Cao Y; Klauber N; Frank D; Brownlee M; Flynn E; Parangi S
STAT3 activation following antigen receptor engagement in B lymphocytes: A new paradigm for STAT proteins.
Volume: 88 Page(s): 1844 - 1844
11/15/1996 Authors: Karras JG; Wang Z; Huo L; Howard RG; Frank DA; Rothstein TL
An activation-specific STAT5 antibody selectively recognizes the tyrosine phosphorylated forms of the erythropoietin receptor and STAT5.
Volume: 88 Page(s): 202 - 202
11/15/1996 Authors: Barber DL; Beattie BK; DAndrea AD; Frank DA
IFN-gamma and IL-4 promote TH1 and TH2 development by differentially modulating high affinity IL-12 receptor expression and IL-12-induced activation of Stat1 and Stat5.
Volume: 88 Page(s): 1100 - 1100
11/15/1996 Authors: Gollob JA; Mahajan S; Rudders SA; Ritz J; Frank DA
Lymphocytes from patients with chronic lymphocytic leukemia contain STAT1 and STAT3 constitutively phosphorylated on serine.
Volume: 88 Page(s): 1171 - 1171
11/15/1996 Authors: Mahajan S; Rudders SA; Ritz J; Frank DA
BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats.
Leukemia Volume: 10 Page(s): 1724 - 1730
11/01/1996 Authors: Frank DA; Varticovski L
Delayed tyrosine phosphorylation and nuclear expression of STAT1 following antigen receptor stimulation of B lymphocytes.
J Immunol Volume: 157 Page(s): 2299 - 2309
09/15/1996 Authors: Karras JG; Huo L; Wang Z; Frank DA; Zimmet JM; Rothstein TL
Antigen-receptor engagement in B cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-gamma activation site.
J Immunol Volume: 157 Page(s): 39 - 47
07/01/1996 Authors: Karras JG; Wang Z; Coniglio SJ; Frank DA; Rothstein TL
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
J Exp Med Volume: 183 Page(s): 811 - 820
03/01/1996 Authors: Carlesso N; Frank DA; Griffin JD
Signal transduction pathways activated by ciliary neurotrophic factor and related cytokines.
Perspect Dev Neurobiol Volume: 4 Page(s): 3 - 18
01/01/1996 Authors: Frank DA; Greenberg ME
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
J Exp Med Volume: 182 Page(s): 1801 - 1806
12/01/1995 Authors: Chauhan D; Kharbanda SM; Ogata A; Urashima M; Frank D; Malik N; Kufe DW; Anderson KC
Oncostatin M induces association of GRB2 with Janus kinase JAK2 in multiple myeloma cells.
Volume: 86 Page(s): 214 - 214
11/15/1995 Authors: Chauhan D; Kharbanda S; Ogata A; Urashima M; Frank D; Malik N; Kufe D; Anderson K
Activation of Stat proteins in cells transformed with Bcr-Abl.
Volume: 86 Page(s): 571 - 571
11/15/1995 Authors: Frank DA; Varticovski L
Thrombopoietin (TPO) induces tyrosine phosphorylation of JAK and STAT proteins.
Volume: 86 Page(s): 1663 - 1663
11/15/1995 Authors: Drachman JG; Sabath DF; Frank DA; Kaushansky K
Tyrosyl phosphorylation and DNA binding activity of STAT proteins in hematopoietic cells transformed by p210 BCR/ABL.
Volume: 86 Page(s): 1042 - 1042
11/15/1995 Authors: Carlesso N; Frank DA; Griffin JD
Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 8665 - 8669
09/12/1995 Authors: Inhorn RC; Carlesso N; Durstin M; Frank DA; Griffin JD
Interleukin 2 signaling involves the phosphorylation of Stat proteins.
Proc Natl Acad Sci U S A Volume: 92 Page(s): 7779 - 7783
08/15/1995 Authors: Frank DA; Robertson MJ; Bonni A; Ritz J; Greenberg ME
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases.
Exp Hematol Volume: 23 Page(s): 1040 - 1048
08/01/1995 Authors: Sattler M; Durstin MA; Frank DA; Okuda K; Kaushansky K; Salgia R; Griffin JD
IDENTIFICATION OF A 93KDA STAT PROTEIN PHOSPHORYLATED FOLLOWING TREATMENT BY GM-CSF OR IL-3 IN HEMATOPOIETIC-CELLS
Volume: 84 Page(s): A224 - A224
11/15/1994 Authors: FRANK D; SALGIA R; BHATT A; GRIFFIN JD; GREENBERG M
CREB: a mediator of long-term memory from mollusks to mammals.
Cell Volume: 79 Page(s): 5 - 8
10/07/1994 Authors: Frank DA; Greenberg ME
Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus.
Science Volume: 262 Page(s): 1575 - 1579
12/03/1993 Authors: Bonni A; Frank DA; Schindler C; Greenberg ME
Biochemical characterization of tyrosine kinase and phosphotyrosine phosphatase activities of HL-60 leukemia cells.
Cancer Res Volume: 48 Page(s): 4299 - 4306
08/01/1988 Authors: Frank DA; Sartorelli AC
Alterations in tyrosine phosphorylation during the granulocytic maturation of HL-60 leukemia cells.
Cancer Res Volume: 48 Page(s): 52 - 58
01/01/1988 Authors: Frank DA; Sartorelli AC
Regulation of protein phosphotyrosine content by changes in tyrosine kinase and protein phosphotyrosine phosphatase activities during induced granulocytic and monocytic differentiation of HL-60 leukemia cells.
Biochem Biophys Res Commun Volume: 140 Page(s): 440 - 447
10/15/1986 Authors: Frank DA; Sartorelli AC

Directory section navigation

Profile